We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Findings Explain How Tumors Guide New Blood Vessel Formation

By LabMedica International staff writers
Posted on 15 Jul 2015
Tumors must generate new blood vessels in order to grow, and a recent paper described a novel Rho-family GTPase activation cascade that was required for the generation of the endothelial cell filopodial protrusions that are necessary for the tubule remodeling that forms the lumen through which the blood will flow.

During the process of new blood vessel formation or angiogenesis, enzymes known as Rho-GTPases influence endothelial cell migration and cell-to-cell adhesion. More...
However, it is not known whether they control formation of vessel lumens, which are essential for blood flow. To clarify this point, investigators at the University of Leeds (United Kingdom) worked with mouse models that allowed them to manipulate levels of enzyme expression during VEGF (vascular endothelial growth factor)-dependent angiogenesis.

They reported in the July 1, 2015, online edition of the journal Nature Communications that lumen formation required early cytoskeletal remodeling and lateral cell–cell contacts, mediated through the RAC1 guanine nucleotide exchange factor (GEF) DOCK4 (dedicator of cytokinesis 4). DOCK family proteins contribute to cell signaling by activating G proteins of the Rho family, such as Rac and Cdc42. Dock4 dependent Rac activation regulates reorganization of the cytoskeleton and was known to lead to the formation of membrane protrusions, which are a crucial step in neuronal development and cell migration.

The investigators showed for the first time that DOCK4 signaling was necessary in angiogenesis for lateral filopodial protrusions and tubule remodeling prior to lumen formation, whereas proximal, tip filopodia persisted in the absence of DOCK4.

Senior author Dr. George Mavria, professor of medicine at the University of Leeds, said, “The finding gives an important indicator of how the protein affects the growth of secondary breast tumors in the brain. The discovery could also enable experts to predict which patients might be at risk of their breast cancer spreading, and develop drugs to prevent the growth of secondary tumors. We want to understand how these tumors form and grow, but we still need to do more research to stop these tumors growing altogether.”

Related Links:

University of Leeds 



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.